Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of Toripalimab In Combination With Rituximab Followed by R-CHOP Regimen (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) for Elderly Naïve Patients With Diffuse Large B-cell Lymphoma

NCT04058470 is registered in ClinicalTrials.gov with Huiqiang Huang as lead sponsor.

NCT NCT04058470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04058470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of Toripalimab In Combination With Rituximab Followed by R-CHOP Regimen (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) for Elderly Naïve Patients With Diffuse Large B-cell Lymphoma
Lead sponsor
Huiqiang Huang
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 24, 2020
Completion date
December 30, 2025
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive anaplastic large cell lymphoma, diffuse large b cell lymphoma, ebv-positive dlbcl, nos, follicular lymphoma grade iiib, high-grade b-cell lymphoma, transformed lymphoma